ORIGINAL ARTICLE

Caspase-2-mediated cell death is required for deleting aneuploid cells

S Dawar¹, Y Lim¹, J Puccini^{1,2}, M White³, P Thomas³, L Bouchier-Hayes⁴, DR Green⁵, L Dorstyn^{1,6} and S Kumar^{1,6}

Caspase-2, one of the most evolutionarily conserved of the caspase family, has been implicated in maintenance of chromosomal stability and tumour suppression. Caspase-2 deficient (*Casp2*^{−/−}) mice develop normally but show premature ageing-related traits and when challenged by certain stressors, succumb to enhanced tumour development and aneuploidy. To test how caspase-2 protects against chromosomal instability, we utilized an *ex vivo* system for aneuploidy where primary splenocytes from *Casp2*^{−/−} mice were exposed to anti-mitotic drugs and followed up by live cell imaging. Our data show that caspase-2 is required for deleting mitotically aberrant cells. Acute silencing of caspase-2 in cultured human cells recapitulated these results. We further generated *Casp2*^{C320S} mutant mice to demonstrate that caspase-2 catalytic activity is essential for its function in limiting aneuploidy. Our results provide direct evidence that the apoptotic activity of caspase-2 is necessary for deleting cells with mitotic aberrations to limit aneuploidy.

Oncogene (2017) 36, 2704–2714; doi:10.1038/onc.2016.423; published online 19 December 2016

INTRODUCTION

Genomic instability, one of the characteristic traits of tumour cells, is often caused by chromosome missegregation or DNA errors arising from replicative, oxidative or oncogenic stress.^{1,2} Genomic instability can either arise from various structural lesions, such as mutations, chromosomal deletions or translocations, or can result from numerical alterations where cells lose or gain copies of whole chromosomes (aneuploidy).³ As the most common chromosome abnormality in humans, aneuploidy is the most common chromosome abnormality in humans, is the cause of many congenital birth defects and is found in the majority of solid tumours.⁴ It is also considered a major underlying contributor to cancer onset and prognosis. Aneuploidy arises from aberrant mitotic events, including defects in centrosome number, kinetochore-microtubule attachments, spindle-assembly checkpoint (SAC), chromosome cohesion or telomeres.⁴

Aberrant mitotic arrest mechanisms normally trigger cell death by apoptosis, which is sometimes referred to as mitotic catastrophe.^{5,6} Apoptosis of cells carrying mitotic defects can be induced by inhibition of DNA damage response and cell cycle checkpoint genes. It has been shown to occur in both a p53-dependent and independent manner, such as in Chk2 inhibited syncytia or in polo-like kinase 2 (Plk 2)-depleted cells.⁶ Inhibition of apoptosis can promote pre-mature mitotic exit (mitotic slippage) and cell cycle progression without chromatid segregation.^{7,8} If these aberrant cells are not removed, they can accumulate and acquire additional mutations, a key mechanism leading to aneuploidy, tumorigenesis and antimetabolic drug resistance.^{4,9,10}

Caspase-2 is one of the most evolutionarily conserved members of the caspase family. Caspase-2 is activated following a variety of cellular insults (metabolic imbalance, DNA damage)¹¹ and

activates other caspases to both initiate and amplify the apoptosis signal.¹² Recent data suggest that *caspase-2*-deficient (*Casp2*^{−/−}) MEFs can readily escape senescence, rapidly immortalise in culture¹³ and show enhanced sensitivity to transformation by oncogenes.^{14,15} In addition, *Casp2*^{−/−} MEFs are more resistant to apoptosis induced by microtubule and spindle poisons¹⁶ and show increased DNA damage following irradiation,¹³ suggesting that *Casp2* loss can promote survival of cells with damaged DNA. Although they develop normally, previous studies have established that *Casp2*^{−/−} mice show enhanced susceptibility to tumorigenesis promoted by *EmMyc*, *MMTV/c-neu* and *K-Ras*,^{14,17–20} increased lymphomagenesis in *Atm*^{−/−} mice,²¹ and diethylnitrosamine-mediated hepatocellular carcinoma,²² indicating a role for caspase-2 as a tumour suppressor. A common feature of the *Casp2*^{−/−} tumours from these mouse models is increased chromosomal instability and aneuploidy.^{13,14,18,19,21,22} These observations suggest that caspase-2 can protect cells against aneuploidy and tumorigenic potential. Some previous *in vitro* observations suggest that caspase-2 has a role in mitotic catastrophe.⁵ Caspase-2 phosphorylation by Cdk1-cyclin B1 complex has been implicated as one mechanism that can prevent caspase-2 activation and cell death,¹² thereby promoting mitotic slippage. However, the molecular details that trigger caspase-2 activation during mitotic arrest are not clear, and it is not known if this directly leads to aneuploidy and tumorigenic transformation. It is also unclear whether aneuploidy seen in *Casp2*^{−/−} tumours and MEFs is a consequence of caspase-2 function in promoting apoptosis of mitotically aberrant cells or due to other roles of caspase-2 in cell cycle.

To address this key question, we established an *ex vivo* system for aneuploidy using primary cells or used a human cell line acutely depleted of caspase-2. Our data show an important role

¹Centre for Cancer Biology, University of South Australia, Adelaide, SA, Australia; ²Departments of Biochemistry and Molecular Pharmacology and Medicine, New York University, New York City, NY, USA; ³SA Genome Editing Facility, School of Biological Sciences and Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia; ⁴Department of Pediatrics-Hematology, Baylor College of Medicine, Houston, TX, USA and ⁵Immunology Department, St Jude Children's Research Hospital, Memphis, TN, USA. Correspondence: Professor S Kumar, Centre for Cancer Biology, University of South Australia, Frome Road, Adelaide 5001, SA, Australia.

E-mail: sharad.kumar@unisa.edu.au

⁶Co-senior authors.

Received 27 May 2016; revised 6 September 2016; accepted 3 October 2016; published online 19 December 2016

for caspase-2 in limiting aneuploidy by deleting chromosomally unstable cells, at least in part *via* Bid-mediated apoptosis. We also tested the importance of caspase-2 catalytic activity in deleting chromosomally unstable cells by generating a *Casp2*^{C320S} mutant mouse. Our results demonstrate that in the absence of caspase-2 activity, cells with defective mitosis become multinucleated and are able to survive long term. Our work establishes a critical role for caspase-2 in the efficient apoptotic removal of potentially tumorigenic cells and provides a basis for the tumour suppressor function of caspase-2.

RESULTS

Caspase-2 deficient cells are a novel model of aneuploidy

To test how caspase-2 loss might lead to aneuploidy, we utilized a cell system that can monitor aneuploidy directly using the PLK1 inhibitor BI 2536. PLK1 plays a critical role in centrosome maturation in late G2/early prophase and is required for establishment of the mitotic spindle.^{23,24} Inhibition of PLK1 has been shown to cause aneuploidy followed by apoptosis of these aneuploid cells.²⁵ As mouse embryonic fibroblasts (MEFs) are highly unstable in culture and cannot be used for such experiments, we established freshly isolated primary mouse splenocytes in cell culture. These cells were stimulated to proliferate by concanavalin A (ConA) for 3 days, supplemented with IL-2 and then exposed to the PLK1 inhibitor BI 2536²⁶ (PLK1-I) for up to 2 days. The cells were then analysed for viability and aneuploidy by time-lapse microscopy before and after PLK1-I washout (Figure 1a). Control experiments showed that freshly isolated *Casp2*^{-/-} splenocytes proliferated faster in culture following stimulation with ConA (Supplementary Figure S1a). In addition, while the cell cycle profiles of both WT and *Casp2*^{-/-} splenocytes in culture were indistinguishable, a significantly increased percentage of *Casp2*^{-/-} splenocytes were able to cycle through G2/M following PLK1-I-mediated mitotic arrest and drug washout (Supplementary Figure S1b). Karyotypic analysis showed that after several days in culture approximately 15% of both WT and *Casp2*^{-/-} cells had become aneuploid. However, following PLK1 inhibition and inhibitor washout *Casp2*^{-/-} splenocytes were significantly more aneuploid than the WT cells (Figure 1b and Supplementary Figure S2a–b). To test if inhibition of caspase activity is sufficient to cause aneuploidy in WT splenocytes, we simultaneously treated cells with a pan-caspase inhibitor and PLK1-I (Figure 1b). Indeed, caspase inhibition was sufficient to significantly increase the proportion of aneuploid WT cells, to the same extent seen in *Casp2*^{-/-} splenocytes treated with PLK1-I. These data also show further enhanced aneuploidy in *Casp2*^{-/-} cells in the presence of a pan-caspase inhibitor, indicating that other caspases may also play a role in limiting aneuploidy. Interestingly, treatment with the microtubule disruptor, Taxol also caused increased aneuploidy in *Casp2*^{-/-} splenocytes (Supplementary Figure S2c). These results indicate that *Casp2* deficiency in primary splenocytes promotes increased aneuploidy following mitotic disruption.

Loss of *Caspase-2* impairs apoptosis of aneuploid and multinucleated cells

Our previous studies have suggested that caspase-2 is required for apoptosis in response to agents that disrupt cell division, such as the microtubule stabilizing drug Taxol.¹⁶ Thus we speculated that increased aneuploidy seen in *Casp2*^{-/-} cells and tumours may be due to the role of caspase-2 in deleting cells carrying mitotic aberrations.⁵ Indeed, following treatment with PLK1-I, *Casp2*^{-/-} splenocytes were more resistant to apoptosis compared to the WT cells (Figure 1c). Similar apoptosis resistance was apparent in *Casp2*^{-/-} splenocytes exposed to Taxol or the Eg5 inhibitor,

Figure 1. Caspase-2 deficiency enhances aneuploidy and delays apoptosis in primary splenocytes. **(a)** Protocol used for time-lapse microscopy, cell viability and aneuploidy analysis in primary splenocytes. **(b)** Quantitation of metaphases showing frequencies of diploid and aneuploid karyotypes in untreated, PLK1 inhibitor (PLK1-I) treated and PLK1-I combined with z-VAD-fmk (pan caspase inhibitor) treated WT ($n = 4$) and *Casp2*^{-/-} ($n = 4$) splenocytes. A total of 50 metaphase spreads were counted per mouse. P values are indicated with $**P < 0.01$, $***P < 0.001$, χ^2 test. **(c)** Quantitation of viable cells in WT and *Casp2*^{-/-} splenocytes treated with PLK1-I for the indicated time points, determined by trypan blue assay. Data represented as mean $\pm$ s.e.m. from four independent experiments. P values are indicated for PLK1-I treated samples with $**P < 0.01$.

monastrol, which affects mitotic spindle assembly and maintenance²⁷ (Supplementary Figure S2d–e).

To investigate whether caspase-2-deficient tumour cells were resistant to PLK1-I-mediated cell death, we treated lymphoma cells from *Atm*^{-/-}/*Casp2*^{-/-} mice (as they exhibit increased high grade aneuploidy²¹), with PLK1-I over 48 h. *Atm*^{-/-}/*Casp2*^{-/-} lymphoma cells similarly showed increased resistance to cell death compared to their *Atm*^{-/-} counterparts (Supplementary Figure S3a). These findings suggest that loss of *caspase-2* impedes apoptosis of tumour cells following mitotic arrest. Since a common cause and consequence of aneuploidy is defective regulation and expression of SAC pathway components,¹⁰ we examined the levels of SAC proteins in *Atm*^{-/-}; *Casp2*^{-/-} lymphomas, which showed higher levels of Bub3, Mad2 and

Cdc20, compared to *Atm*^{-/-} tumours (Supplementary Figure S3b). We also detected higher levels of these SAC proteins in splenocytes following PLK1-I treatment (data not shown). This may be due to either the increased proliferative capacity of these cells²¹ and/or increased number of aneuploid cells in the *Casp2*^{-/-} tumour cells. Alternatively, this may indicate an intrinsic yet uncharacterized defect due to *caspase-2* deficiency. Together these results suggest that caspase-2 deficiency enhances survival of aneuploid cells, which harbour aberrant levels of SAC proteins that can further contribute to enhanced mitotic progression following *caspase-2* loss.

Live imaging of aberrant mitotic arrest and multinucleation in *Caspase-2*-deficient cells

To examine whether caspase-2 is required for killing cells during mitosis *in vivo*, we subjected untreated and PLK1-I-treated splenocytes to live cell imaging. In control experiments there were no apparent differences in cell morphology or cell size between the WT and *Casp2*^{-/-} splenocytes over time in culture. Both WT and *Casp2*^{-/-} splenocytes treated with PLK1-I showed aberrant mitotic cells with altered morphology and multiple nuclei (Figures 2a and b). However, such aberrations were more frequent in *Casp2*^{-/-} cells compared to the WT cells. A close examination of the imaging data indicated that, while mitotic cell deaths were apparent in both genotypes, more WT splenocytes underwent apoptosis compared to the *Casp2*^{-/-} cells (Figure 2c). These observations were even more notable following washout of PLK1-I,

with increased survival of multinucleated and abnormally nucleated *Casp2*^{-/-} cells (Movies 1 and 2). These data suggest that the loss of caspase-2 results in reduced mitotic cell deaths.

Acute ablation of *caspase-2* enhances survival of multinucleated cells

To further examine if acute loss of caspase-2 (as opposed to chronic absence in cells derived from knockout mice) would result in a similar inability to remove cells with mitotic damage, we used small interfering RNA (siRNA) to silence *CASP2* in U2OS cells (Supplementary Figure S4) expressing a green fluorescent protein (GFP)-tagged Histone H2B construct²⁸ and also subjected these cells to live cell imaging (Movies 3 and 4). As observed with the *Casp2*^{-/-} splenocytes, there were significantly less apoptotic cells in the *CASP2* siRNA transfected U2OS cells at both 24 and 48 h following addition of PLK1-I compared to the control siRNA treated cells (Figures 3a and b; Movies 5 and 6). While there were no changes in morphology or cell divisions between the untreated control cells and *CASP2* depleted cells (Movies 3 and 4), following PLK1-I washout over a 0–24 h period, there were significantly more aberrantly shaped multinucleated cells in the *CASP2*-depleted population (Movies 7 and 8). In addition following 24–48 h of PLK1-I washout, while many control cells still died as they attempted to undergo mitosis, *CASP2* depletion resulted in increased survival of multinucleated cells and later lead to the accumulation of 'giant' cells with aberrant morphology following 48 h (Figures 3c and d and Movies 7 and 8). Interestingly,

Figure 2. Loss of Caspase-2 leads to accumulation of multinucleated cells and reduced cell death in primary splenocytes following PLK1-I treatment. **(a)** Representative images from live cell imaging of WT and *Casp2*^{-/-} splenocytes stained with Acridine Orange, showing cells with multiple nuclei (arrows) and dead cells (arrow heads) at indicated time points following PLK1-I treatment. Scale bar = 50 μ m. **(b, c)** Quantitation of **(b)** multinucleated cells and **(c)** dead cells from WT and *Casp2*^{-/-} splenocytes at the indicated time points following PLK1-I treatment. Data represented as mean $\pm$ s.d. from three independent experiments. *P* values are indicated with ***P* < 0.01, ****P* < 0.001.

following *CASP2*-depletion, cells failed to enter metaphase but nuclei nevertheless underwent division to give rise to live multinucleated cells, whereas many of the control siRNA treated

cells eventually entered metaphase and died soon after (Figure 3e and Movies 5–8). Imaging of the fate of single cells demonstrate control siRNA treated cells dying following PLK1-I treatment over

Figure 3. Acute knockdown of *CASP2* affects cell death and promotes accumulation of cells with multiple and abnormal nuclei following PLK1-I addition. **(a)** Representative images from live cell imaging of GFP-tagged histone H2B expressing U2OS cells treated with Control siRNA or *CASP2* siRNA together with PLK1-I at the indicated time points, displaying dead cells (arrows). Scale bar = 50 μ m. **(b)** Quantitation of dead cells in U2OS Control siRNA or *CASP2* siRNA at indicated time points. Data represented as mean $\pm$ s.d. from three independent experiments. *P* values are indicated with $**P < 0.01$, $***P < 0.001$. **(c)** Representative images from live cell imaging of H2B-GFP U2OS cells treated with Control siRNA or *CASP2* siRNA at the indicated time points following PLK1-I washout, displaying multinucleated cells (arrows) and cells with abnormally large nuclei (arrow heads). Scale bar = 50 μ m. **(d)** Quantitation of dead cells, multinucleated cells and cells with abnormal nuclei at indicated time points following PLK1-I washout. Data represented as mean $\pm$ s.d. from three independent experiments. *P* values are indicated with $**P < 0.01$, $***P < 0.001$. **(e)** Quantitation of cell cycle events following PLK1-I induced mitotic arrest. Data represented as mean $\pm$ s.d. from three independent experiments. *P* values are indicated with $**P < 0.01$. **(f)** Clonogenic assay. Representative image of crystal violet stained colonies in Control or *CASP2* siRNA-transfected U2OS cells treated with PLK1-I (100 nM) for 48 h and cultured over 11 days. Experiment was carried out in triplicate and the colony was defined to consist of at least 50 cells. Quantitation of colony forming efficiency from three independent experiments is shown. Data represent mean $\pm$ s.e.m. $***P < 0.001$.

Figure 4. Caspase-2 activation in U2OS cells during mitotic arrest is required for apoptosis. **(a)** Caspase-2 Venus-tagged constructs used for BiFC assay and representative images showing caspase-2 activation at 24 h following PLK1-I treatment of U2OS cells. Scale bar = 20 μm. Quantitation of BiFC fluorescence is indicated. *** $P < 0.001$. **(b)** Caspase activity assays in U2OS cells treated with control or *CASP2* siRNA over the indicated time points following PLK1-I, assessed by cleavage of DEVD-AMC. Data represented as mean ± s.d. from three independent experiments. ** $P < 0.01$, *** $P < 0.001$. **(c)** Immunoblot analysis of caspase-2, caspase-3, PARP and Bid cleavage in U2OS cells treated with control or *CASP2* siRNA over the indicated time points following PLK1-I.

24 h and following washout (Supplementary Figure S5a and b). We did not observe any differences in the frequency of anaphase bridge formation but demonstrate *CASP2* siRNA treated cells attempt (but fail) to undergo anaphase and are still able to survive over 48 h post PLK1-I washout (Supplementary Figure S5b). Together these findings suggest that *CASP2* depletion can contribute to an increased incidence of mitotic slippage and survival of aberrant cells following PLK1-I treatment.²⁹

To examine the long-term effect of *CASP2* silencing on the survival of PLK1-I treated multinucleated and/or aneuploid cells we carried out a clonogenic assay and demonstrated a greater than fivefold increase in colony formation in cells depleted of *CASP2* (Figure 3f). These findings indicate that caspase-2 depletion can enhance the clonogenic survival of aneuploid cells. Together these experiments clearly demonstrate that both acute silencing or ablation of caspase-2 is sufficient for enhanced accumulation and survival of cells with defective mitoses following PLK1 inhibition, which would otherwise have been deleted by cell death.

Caspase-2 activation is required for apoptosis following mitotic arrest

To assess caspase-2 activation following PLK1-I treatment we used the bimolecular fluorescence complementation (BiFC) assay with full-length *CASP2* gene (C320A)³⁰ and demonstrate caspase-2

dimerization and activation following PLK1-I addition (Figure 4a). Analysis of the kinetics of PLK1-I-mediated cell death and caspase activation also demonstrated significantly reduced caspase-3-like activity in *CASP2* siRNA treated U2OS cells (Figure 4b). We also examined the cleavage dynamics of various apoptotic proteins in U2OS cells following acute silencing of *CASP2*, and found that *CASP2* siRNA treatment markedly reduced the cleavage of both caspase-3 and PARP following PLK1-I treatment (Figure 4c).

Several studies have shown that caspase-2 activation can occur upstream of mitochondrial outer membrane permeabilization (MOMP).^{12,31–33} Once active, caspase-2 cleaves Bid and this truncated Bid (tBid) induces MOMP and apoptosis.^{16,34} An examination of Bid protein levels in U2OS cells following *CASP2* siRNA treatment also displayed markedly reduced cleavage (Figure 4c). These results suggest that the increased aneuploidy associated with the loss of caspase-2 is due to the loss of caspase activity, which is required for Bid-mediated apoptosis.

Primary cells from Caspase-2 catalytic mutant mouse show enhanced aneuploidy

The catalytic activity of caspase-2 has been shown to be required to inhibit tumorigenesis and mutation of the catalytic Cysteine residue (C320) in the caspase-2 results in the loss of its tumour suppressor function.³⁵ As the tumour suppressor function of caspase-2 could be due to its ability in deleting aneuploid cells we

Figure 5. Generation and validation of a *Casp2*^{C320S} mice. **(a)** A representative DNA agarose gel image from genotyping of WT, *Casp2*^{+/C320S} (heterozygous) and *Casp2*^{C320S/C320S} (homozygous) mice. The size of expected DNA fragments generated per genotype are indicated (bp). **(b)** DNA sequencing confirmation of the different genotypes as indicated. The red and blue arrows indicate the point mutation sites (G, G/C or C) and the silent mutation site (T, T/A or A), respectively. **(c)** Immunoblot analysis of caspase-2 expression in splenocytes from WT and *Casp2*^{C320S/C320S} mice. β -actin is shown as loading control. **(d)** Genotype frequencies of the progeny from *Casp2*^{+/C320S} (heterozygous) intercrossing including observed and expected numbers of offspring. Observed and expected frequency (%) is indicated in parentheses. Statistical comparison was performed by χ^2 test.

next examined the requirement of caspase-2 catalytic activity in limiting aneuploidy and survival of multinucleated cells. To do this we generated a C320 mutant mouse allele, *Casp2*^{C320S} by CRISPR/Cas9 (Figure 5). We introduced a single point mutation that generated an XhoI site to facilitate genotyping of *Casp2*^{C320S} heterozygous (*Casp2*^{+/C320S}) and homozygous (*Casp2*^{C320S/C320S}) mice (Figure 5a). DNA sequencing confirmed the introduction of a G to C point mutation resulting in a C320S amino acid substitution (Figure 5b). Immunoblot analysis of caspase-2 protein expression in primary splenocytes confirmed expression levels of Caspase-2 mutant protein were comparable to WT (Figure 5c). We have generated and maintained a colony of *Casp2*^{C320S} mice by intercrossing *Casp2*^{+/C320S} mice over 6 months. Consistent with our *Casp2*^{-/-} mice breeding data, *Casp2*^{C320S/C320S} mice are born at normal mendelian frequency (Figure 5d) with males and females produced at normal 1:1 ratio. Observation of these mice over a 6-month period has not detected any overt phenotypic differences compared to WT animals.

We next examined PLK1-I induced aneuploidy and cell death in splenocytes from *Casp2*^{C320S/C320S} mice (designated as *Casp2*^{C320S}). Consistent with our findings in *Casp2*^{-/-} splenocytes, *Casp2*^{C320S} splenocytes showed significantly greater level of aneuploidy (Figure 6a) and increased resistance to cell death (Figure 6b) following PLK1-I treatment. In addition, live cell imaging of *Casp2*^{C320S} splenocytes demonstrated increased numbers of surviving multinucleated cells and reduced number of dying/dead cells (Figures 6c–e). These are the first findings detailing the requirement of caspase-2 catalytic activity in limiting aneuploidy. Importantly they conclusively demonstrate a critical role of caspase-2 function in apoptosis of multinucleated and/or aneuploid cells following mitotic stress.

DISCUSSION

This study demonstrates an important requirement for caspase-2 enzymatic activity in the apoptotic removal of mitotically aberrant cells in response to replicative stress. We describe the generation of *Casp2*^{C320S} mutant mice and provide the first demonstration that caspase-2 catalytic mutation increases susceptibility to aneuploidy. These data are consistent with an *in vitro* study showing a potential function for caspase-2 in mitotic catastrophe.⁵ Our data further demonstrate that loss of caspase-2 promotes the long-term survival of mitotically aberrant cells that could potentially become tumorigenic.

Our imaging data suggest that caspase-2 activation occurs when a specific mitotic checkpoint is breached. Interestingly, closer analyses of real time movies show that in contrast to WT cells, many PLK1 inhibited *Casp2*^{-/-} cells appear to exit mitosis in prometaphase without entering metaphase. Instead, cells enter an interphase-like state as multinucleated and/or aneuploid cells, with enhanced ability to survive. Our findings indicate that loss of caspase-2 affects mitosis during the prometaphase to metaphase transition, which may include spindle assembly or chromosome alignment to spindle. In previous analyses using MEFs we did not detect abnormalities in spindle formation or formation of anaphase bridges in *Casp2*^{-/-} cells during mitosis and following mitotic arrest.¹³ Further defining the exact mitotic checkpoint and requirement for caspase-2 would be important in future studies.

Several studies have previously implicated caspase-2 in cell cycle regulation and mitotic cell death.^{5,16,36–38} Activation of the SAC by disrupting microtubule stability has been shown to require caspase-2 for induction of cell death.¹⁶ Caspase-2 has also been

Figure 6. Caspase-2 catalytic cysteine mutant enhances aneuploidy. **(a)** Quantitation of metaphases showing frequencies of diploid and aneuploid karyotypes in untreated and PLK1 inhibitor (PLK1-I) treated WT ($n=3$) and *Casp2*^{C320S/C320S} (designated as *Casp2*^{C320S}) ($n=3$) splenocytes. A total of 50 metaphase spreads were counted per mouse. P values are indicated with $**P < 0.01$, $***P < 0.001$, χ^2 test. **(b)** Quantitation of viable cells in WT and *Casp2*^{C320S} splenocytes treated with PLK1-I for the indicated time points, determined by trypan blue assay. Data represented as mean $\pm$ s.e.m. from three independent experiments. P values are indicated with $**P < 0.01$. **(c)** Representative images from live cell imaging of WT and *Casp2*^{C320S} splenocytes stained with Acridine Orange, showing cells with multiple nuclei (arrows) and dead cells (arrow heads) at the indicated time points following PLK1-I treatment. Scale bar = 50 μ m. **(d, e)** Quantitation of multi nucleated cells **(d)** and dead cells **(e)** at the indicated time points, following PLK1-I washout. Data represented as mean $\pm$ s.d. from three independent experiments. P values are indicated with $**P < 0.01$, $***P < 0.001$.

implicated in mitotic catastrophe, via MOMP-dependent and p53-independent apoptosis.^{5,7} Our cell death data in conjunction with our live cell imaging results demonstrate that cells treated with PLK1-I underwent a mitotic arrest that eventually led to mitotic death, consistent with the published definition of mitotic catastrophe.^{6,39,40} Cleavage of caspase-2, caspase-3 and PARP following PLK1-I confirmed cells are undergoing apoptosis.

Silencing of caspase-2 has previously been shown to promote cell cycle progression and mitotic slippage, resulting in asymmetric cell division and aneuploidy.⁷ Our own studies have

demonstrated loss of caspase-2 enhances DNA damage, micronuclei and aneuploidy in cultured cells and in tumours.¹³ The increased frequency of micronuclei formation is associated with lagging chromosomes, a likely cause of aneuploidy in these cells. Causes of lagging chromosomes include unresolved merotelic attachment of the kinetochore and microtubules and/or cytokinesis failure. Aberrant merotelic attachments can still satisfy the SAC, so that anaphase can take place despite their presence.^{41,42} Merotelic attachments are often detected in cells that carry abnormal centrosome number and it is important to note that

supernumerical centrosomes can arise from cytokinesis failure. It is not yet known whether cells deficient for caspase-2 have aberrant centrosome number or exhibit aberrant cytokinesis, features that may explain the occurrence of lagging chromosomes and enhanced aneuploidy.

A defective SAC pathway can induce premature anaphase, lagging chromosomes and micronucleus formation without detectable mitotic arrest.^{43,44} It is plausible that in addition to a role in cell death, caspase-2 has an additional role in SAC regulation. However, many observations from *Casp2*-deficient mice are consistent with caspase-2 playing a role in removing aberrant cells by apoptosis. Although *Casp2*-deficient mice do not spontaneously develop tumours, caspase-2 loss results in animals that are sensitized to stress, as apparent from a mild premature ageing phenotype.^{45,46} Increased oxidative stress and more damaged cells in the liver of aged *Casp2*^{-/-} mice, and the increased genomic instability seen in tumours from *EμMyc;Casp2*^{-/-}, *Atm*^{-/-};*Casp2*^{-/-}; and *MMTV/c-neu;Casp2*^{-/-} mice, are all consistent with a role of caspase-2 in deleting aneuploid cells by apoptosis. Our findings that *Atm*^{-/-};*Casp2*^{-/-} lymphoma cells are more resistant to PLK1-I-mediated cell death may have important implications for drug resistance in lymphoma treatment.⁴⁷ It is important to note that, while in most dividing cells caspase-2 is inactive,³⁶ our findings demonstrate that following mitotic stress, a small population of *Casp2*^{-/-} cells are resistant to apoptosis and survive as multinucleated and aneuploid cells. Importantly, these cells acquire an ability to survive long term in culture, an attribute likely to contribute to enhanced cellular transformation and tumorigenic potential.

Moreover, caspase-2 phosphorylation at Ser340 by the mitosis-promoting kinase, cdk1-cyclin B1, maintains it in an inactive state during mitosis and activation of caspase-2 can lead to mitotic catastrophe.³⁶ Consistent with these findings, our study now shows that catalytic inactivation of caspase-2 prevents mitotic cell death. Importantly, our data demonstrate that caspase-2 inactivation or deficiency directly enhances aneuploidy. Furthermore, caspase-2 silencing enhances clonogenic survival of multinucleated and aneuploidy cells, suggesting a mechanism by which loss of caspase-2 can enhance susceptibility to tumorigenic transformation and underpins the mechanism by which caspase-2 acts as a tumour suppressor.

While other caspases, such as caspase-3 and caspase-9, have been shown to play a role in deleting cells with damaged DNA, micronuclei or polyploidy,^{48,49} our studies indicate that caspase-2 plays a dominant role in deletion of mitotically aberrant cells in our system, since caspase-2 deficiency promotes aneuploidy to a similar extent as does zVAD-mediated inhibition of caspases in WT cells. We show that caspase-2 can limit aneuploidy via Bid-mediated apoptosis, which further support previous findings that caspase-2 functions upstream of MOMP, caspase-9 and caspase-3 activation.⁵ In addition, we know from mouse models that this function is independent of caspase-2 interacting proteins RAIDD and PIDD, as loss of these genes does not promote increased aneuploidy in cells in culture or in tumours.¹⁷ Interestingly, previous studies have shown that Bid does not appear to be essential for DNA damage or replicative stress-induced apoptosis or cell-cycle arrest.⁵⁰ Therefore it is possible that caspase-2 may also be able to promote apoptosis of mitotically aberrant cells in a Bid-independent manner.

This study has established a connection between *caspase-2* deficiency and a multi nucleated and aneuploid phenotype by attenuation of apoptosis. This multinucleation and aneuploid phenotype in *Casp2*^{-/-} cells appears to be specific in response disruption of the spindle assembly during mitosis. We propose that, along with the conventional intrinsic apoptosis pathway, caspase-2-dependent cell death augments efficient removal of cells with chromosomal defects to limit aneuploidy *in vivo*. Additional studies are required to determine the factors required

for survival and proliferation of *Casp2*^{-/-} aneuploid cells, and whether these cells have enhanced tumorigenic ability and drug-resistance. Such knowledge will be essential for understanding and defining future chemotherapeutic strategies in drug-resistant cancers.

MATERIALS AND METHODS

Mice

Casp2^{-/-} mice^{14,51} have been described previously. Animals were maintained in specific pathogen-free conditions at the SA Pathology Animal care facility and all animal breeding and studies were approved by the SA Pathology/Central Northern Adelaide Health Services Animal Ethics Committee. An equal number (between 3 and 5) of healthy adult mice (6–8 weeks) of each genotype were randomly euthanized for primary cell collection for each experiment. Selection of mice per genotype was not blinded.

Generation of *Casp2*^{C320S} mutant mice

CRISPR/Cas9 technology was used to generate *Casp2*^{C320S} mutant mice by SA Genome Editing Facility (Adelaide, Australia). Guide oligonucleotides (Geneworks, Thebarton, SA, Australia) were denatured at 95 °C for 5 min and annealed at 25 °C before being ligated into BbsI linearized px330 vector (Addgene, Cambridge, MA, USA). A template for *in vitro* transcription was generated by PCR amplification of the px330 vector using a forward primer containing a 5' T7 promoter sequence and a reverse primer that bound the TracR sequence. *In vitro* transcription was performed using the HiScribe T7 *In Vitro* Transcription Kit (NEB, Ipswich, MA, USA) and transcribed gRNA was purified using RNeasy Mini Kit (QIAGEN, Hilden, Germany). The donor oligonucleotide (Integrated DNA Technologies, Coralville, IA, USA) contained the intended point mutation as well as a silent mutation that introduced a XhoI restriction site that was used to screen mutant alleles. To produce Cas9 mRNA, Cas9 plasmid was linearized using XhoI restriction enzyme (NEB) and mRNA was transcribed using mMessage mMachine T7 Ultra Kit (Life technologies, Carlsbad, CA, USA) followed by capping and polyadenylation. C57BL/6 females were superovulated by injecting 5IU PMSG (Folligon; Intervet India, Pune, Maharashtra, India) followed by 5IU hCG (Chorulon; Intervet India) 47.5 h later. Superovulated females were mated to male C57BL/6 mice and fertilized oocytes were collected from oviducts in a Hepes buffered flushing and holding medium (FHM) (Merck Millipore, Darmstadt, Germany). Oocytes were maintained in KSOM^{AA} (Merck Millipore) at 37 °C in 5% CO₂ and were screened for the presence of two pronuclei to indicate fertilization. Fertilized oocytes were microinjected with a buffered solution containing Cas9 mRNA (100 ng/μl), sgRNA (50 ng/μl) and donor oligo (100 ng/μl) in FHM before being transferred to the oviduct of a pseudopregnant Swiss female mouse. For genotyping of mutant mice including founder mice, genomic DNA was extracted from postnatal day 10 tail tissue using High Pure PCR Template Preparation Kit (ROCHE, Basel Schweiz, Switzerland). A 497 bp fragment containing the putative mutation was amplified by PCR and digested with XhoI restriction enzyme. Mutant alleles showed digested products of 321 and 176 bp.

The following oligonucleotides were used for the generation of *Casp2*^{C320S} mice:

Donor Oligo:

5'-TTGACAAATGCTAACTGTCCAAGTCTACAGAACAAGCCAAAAATGTTCTTCA TCCAAGCATCTCGAGGAGGTGAGTGCCTGGCAAACCAGCACCTGGGTGGTG GCTCCTGGGAGCCTCCACCAG-3'.

(C; point mutation target; A, silent mutation for XhoI site introduction).

Forward Guide Oligo: 5'-CACCGTTCATCCAAGCATGTCGTGG-3'

Reverse Guide Oligo: 5'-AAACCCACGACATGCTTGGATGAAC-3'

T7 PCR Oligo: 5'-TTAATACGACTCACTATAGTTCATCAAGCATGTCGTGG-3'

The following oligonucleotides were designed for genotyping *Casp2*^{C320S} mice:

F-mC2-C320S: 5'-TTTGCCCCAACCTTTTCAGT-3'; R-mC2-C320S: 5'-CCCA TGCATTGGGAGACACT-3'.

Cell culture

Primary cells were collected from at least three independent mice per genotype (sample size is indicated in figure legends) and the analysis of primary cells was performed in randomized and blinded manner. Primary splenocytes were extracted from 6–8-week-old WT, *Casp2*^{-/-} and *Casp2*^{C320S}

mice. Briefly, spleens were homogenized and cells filtered through 40 µm nylon mesh filter and incubated in red blood cell lysis buffer (155 mM NH₄Cl, 10 mM NaHCO₃) for 5 min at room temperature. Cells were stimulated with 10 µg/ml concanavalin A (ConA) (Sigma-Aldrich, St Louis, MO, USA) for the first 48 h followed by culturing in 100 U/ml recombinant mouse IL-2, at 37 °C with 5% CO₂ in DMEM media (Sigma-Aldrich) supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS, USA), 50 µM β-mercaptoethanol (Amersham, GE Healthcare Life Sciences, Little Chalfont, UK), non-essential amino acid mix (Sigma-Aldrich), 0.2 mM l-glutamine (Sigma-Aldrich), 15 mM HEPES (Sigma-Aldrich) and 100 µM penicillin/streptomycin (Sigma-Aldrich). The human osteosarcoma (U2OS) cell line (obtained from ATCC) were maintained at 10% CO₂ in DMEM media (Sigma-Aldrich) supplemented with 10% fetal bovine serum (JRH Biosciences), 0.2 mM l-glutamine (Sigma-Aldrich), 15 mM HEPES (Sigma-Aldrich) and 100 µM penicillin/streptomycin (Sigma-Aldrich). Where indicated, cells were treated with the PLK-1 inhibitor BI 2536 (50 nM) (Axom medchem, Hanzepin, Groningen, Netherlands), over 48 h, Paclitaxel (100 nM) (Sigma-Aldrich) or the Eg5 inhibitor monastrol (5 µM) (Sigma-Aldrich) over 72 h. Cell synchronization was carried out using either a single-thymidine (for BiFC) or double-thymidine (for immunoblotting) block (2 mM) prior to treatment with BI 2536 (100 nM). Cell viability was determined by trypan blue dye exclusion. For population doubling times, primary splenocytes were seeded at 1×10^6 in six-well plates at day 0. Cells were harvested on day 6 and 8 following Con-A stimulation and number of viable cells were estimated by trypan blue exclusion. The doubling time was calculated as: t/n ; where t = number of days for n population doublings to occur and n = number of population doublings and was calculated as $n = \log(B/A)/\log 2$; where A = initial cell number; B = final cell number. Healthy, exponentially growing cells were used in all experiments.

Live cell imaging

Freshly isolated splenocytes were imaged in 35 mm imaging dishes (µ-Dish 35 mm, low, Ibidi, Martinsried, Germany) coated with 0.01% poly-L-lysine (Sigma-Aldrich). Cells were either untreated or treated with BI 2536 (24 h after drug washout) and stained with 1 µM Acridine dye (Sigma-Aldrich) prior to imaging. U2OS cells stably expressing GFP-tagged histone H2B were generated using the pBOS-H2BGFP vector (BD, Biosciences, San Jose, CA, USA) and were grown in µ-slide eight-well chambered dishes (Ibidi). U2OS cells were transfected with control or CASP2 siRNA (as described below) prior to treatment with BI 2536 and imaged for 48 h. Following washout of BI 2536, cells were imaged for a further 48 h. Frames were captured at 3 min intervals. All live cell imaging was repeated with at least three independent batches of cells, and the average number of multinucleate, 'giant' and dead cells per high-power field was calculated and statistically analysed. Live cell imaging was carried out in Cell Voyager CV1000 Confocal Scanner (Yokogawa Electric Corporation, Tokyo, Japan). Images were trimmed using QuickTime Player.

Knockdown of caspase-2 expression by siRNA

Caspase-2 knockdown by siRNA has been previously described.⁴⁵ Two different sets of siRNA (purchased from GenePharma, Shanghai, China) were used to minimize any potential off-target effects, with the following sequences; CASP2 siRNA-1 (5'-ACAGCUUGUUGAGCGAAdTdT-3'), CASP2 siRNA-2 (5'-GUUGUUGAGCGAAUUGUUATT-3'), control siRNA (5'-UAAGCGUAUGAAGAGAUACTT-3'). All transfections were carried out using Trans IT-TKO transfection reagent (Mirus, Madison, WI, USA) for 48 h according to manufacturer's instructions. Briefly, U2OS cells (1×10^5) were seeded into 60 mm dishes in 2 ml complete medium and allowed to adhere for 16–24 h. 2.5 µl (20 µM siRNA) and 3 µl of TransIT-TKO siRNA transfection reagent (Mirus) were diluted to 100 µl in Opti-MEM (Sigma-Aldrich) and incubated for 15 min at room temperature. The diluted siRNA and transfection reagent were combined and incubated for a further 15 min at room temperature and then overlaid onto cells. After 30 h incubation at 37 °C in the transfection complexes, the media was replaced and cells were allowed to recover for 12 h before treatment with BI 2536 (100 nM) for 48 h and harvesting for protein analysis. Knockdown experiments were repeated at least three times and the results statistically analysed.

Cytogenetic analysis

Preparation of chromosome spreads from untreated and BI 2536-treated splenocytes was carried out as previously described¹³ by adding colcemid (20 ng/ml), 4 h prior to harvesting cells by trypsinization, hypotonic treatment (0.075 M KCl) and fixation in fresh ice cold Carnoy's fixative

(methanol:glacial acetic acid at 3:1) for 10 min at 37 °C. Cells were centrifuged at 1000 rpm, washed three times in Carnoy's fixative and dropped onto wet glass slides, air dried and then placed in a 60 °C oven overnight. Cells were stained with DAPI and chromosomes quantitated by epifluorescence microscopy (model BX51; Olympus, Tokyo, Japan) and camera (UCMAD3/CVM300, Olympus). Cells were visualized under $\times 40$ or $\times 100$ ULAPO objective lens with NA = 1.5. Images were processed using Olysia BioReport Software (Olympus) and manually merged using Adobe Photoshop 6.0 software. Cytogenetic analysis was repeated with at least three different batches of cells, and the average number of chromosomes per cell per high-power field was calculated and statistically analysed. Chromosomal counts were carried out in a randomized and blinded manner.

Caspase activation assays

Caspase substrate activity assays using DEVD-AMC were carried out as previously described.⁵² BiFC analysis for caspase-2 activation was performed as described previously with minor modification.⁵³ Briefly, full-length caspase-2 protein was fused to fragments of Venus (super enhanced YFP) constructs to yield CASP2_{FL}-VN (Venus fragment 1-173) and CASP2_{FL}-VC (Venus fragment 155-239). 2×10^4 U2OS cells in complete culture medium were seeded onto 13 mm glass coverslips (Thermo Fisher Scientific, Waltham, MA, USA) in a 24-well plate and incubated overnight at 37 °C in a 10% CO₂ incubator. The next day cells were co-transfected with 150 ng of the pBiFC-HA-Caspase-2 FL (C320A)-VC155 and pBiFC-HA-Caspase-2 FL (C320A)-VN173 for BiFC and 10 ng of pDsRed-Mito (Clontech, Mountain View, CA, USA) as a transfection reporter plasmid, using Eugene HD reagent (Promega, Madison, WI, USA) according to the manufacturer's instruction. After incubation for 5 h, the medium was replaced with complete culture medium containing z-VAD-fmk (20 µM) and cells were incubated a further 24 h at 37 °C in a 10% CO₂ incubator. Cells were then synchronized with thymidine (2 mM; Sigma-Aldrich) and incubated for 24 h at 37 °C in a 10% CO₂ incubator. Cells were washed with pre-warmed PBS and covered with complete culture medium containing DMSO (control) or z-VAD-fmk (20 µM) with or without PLK1-I (BI 2536-100 nM). Cells were fixed at 24 h and 48 h after treatment. Caspase substrate activity experiments were repeated at least three times, and results statistically analysed. CX40 epifluorescence microscope (Olympus) was used for imaging BiFC and analysis. To quantify BiFC-positive cells, total 1065 (24 h control), 394 (24 h BI 2536), 926 (48 h control) and 391 (48 h BI 2536) cells were counted in three different areas in four independent experiments. Statistical analysis was carried out in GraphPad Prism, Version 6.05 (GraphPad, GraphPad Software Inc., La Jolla, CA, USA).

Immunoblotting

Protein lysates were prepared from primary splenocytes or tumour tissue by cell lysis and/or homogenization in RIPA buffer [25 mM Tris/HCl pH 7.4, 150 mM NaCl, 1% nonyl-phenoxypolyethoxyethanol (NP-40), 1% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS)], in the presence of protease/phosphatase inhibitor cocktail (Thermo Fisher Scientific). Homogenates were treated by three freeze/thaw cycles in liquid nitrogen, clarified by centrifugation at 13.2 K rpm and protein concentration determined by BCA quantitation (Bio-Rad, Hercules, CA, USA). 30 or 50 µg of lysates were resolved on 4–20% Mini-PROTEAN TGX gel (Bio-Rad), 12or 15% SDS-PAGE gel as appropriate and transferred onto PVDF membrane and probed for the specified antibody for 2 h at room temperature or overnight at 4 °C. Secondary antibodies, conjugated with horseradish peroxidase, alkaline phosphatase or Cy5 (Millipore/GE Healthcare, Chicago, IL, USA), were incubated at room temperature for 2 h. Proteins were visualized using ECF or ECL (Millipore/GE Healthcare). The following antibodies were used: caspase-2 (clone 11B4), PARP (#9542), caspase-3 (#9662), Mad2 (#4636) (Cell Signalling Technology, Danvers, MA, USA), cyclin B1 (#sc-245) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), β-actin (#A5316), Bub3 (#B7811) (Sigma-Aldrich), Bid (#AF846) (R&D Systems, Minneapolis, MN, USA) and Cdc20 (#ab183479) (Abcam, Cambridge, MA, USA). Immunoblotting experiments were repeated at least three times, and the results were statistically analysed.

Clonogenic assays

Clonogenic assays were carried out as previously described.⁵⁴ Briefly, U2OS cells were seeded at 1×10^5 cells in a 60 mm dish. Cells were transfected with either control or CASP2 siRNA for 48 h followed by treatment with PLK1-I (100 nM) for a further 48 h. Cells were then harvested and reseeded

at a density of 800 viable cells per well in a six-well plate, in triplicate. After culturing 11 days, the colonies were stained with 6% glutaraldehyde (Ajax Finechem, NSW, Australia) and 0.5% crystal violet (Sigma-Aldrich) and counted using a stereomicroscope (Nikon, Tokyo, Japan). A colony was defined as consisting of at least 50 cells and experiments were repeated at least three times for statistical analysis. Colony forming efficiency (%) = (total number of colonies/number plated cells) 100%.

Flow cytometry

Splenocytes (2×10^6) either untreated or treated with BI 2536 (50 nM) were fixed in 70% v/v ethanol and stored at -20°C . Fixed cells were rehydrated by washing 2–3 times in PBS with centrifugation at $500 \times g$ for 5 min. Cells were then permeabilized with 0.25% v/v Triton X-100/PBS for 10 min at room temperature and then incubated in staining solution containing 40 $\mu\text{g}/\text{mL}$ RNase A (Roche) and 25 $\mu\text{g}/\text{mL}$ propidium iodide (Sigma-Aldrich), for at least 3 h at room temperature. Cells were stored at 4°C then analysed on an FC500 flow cytometer (Beckman Coulter, Brea, CA, USA). At least 50 000 events were recorded per sample and results were statistically analysed. Cellular debris and doublets were excluded from the analysis based on non-linearity on a doublet discrimination plot. Data analysis was performed using Multicycle AV on FCS Express Flow Cytometry Research Edition Version 4 (DeNovo Software, Glendale, CA, USA).

Statistical analysis of data

Statistical analysis was carried out in GraphPad Prism, Version 6.05 (GraphPad, GraphPad Software Inc) or using Microsoft Excel 2010. A two-sided Student's *t*-test was used to estimate differences between data groups, unless otherwise stated. Data are expressed as mean $\pm$ s.e.m. *P*-values < 0.05 were considered as statistically significant. The sample sizes were determined by power analyses, based on variation shown in our previous experiments and predicted effect sizes considered to be biological significant. No data were excluded from any analyses and all replicates are true biological replicates. The statistical test used and the sample sizes for individual analyses are provided within the figure legends.

ABBREVIATIONS

ATM, Ataxia telangiectasia mutated; BUB3, budding uninhibited by benzimidazoles 3 homolog; CDC20, Cell Division Cycle 20; ConA, Concanavalin A; Mad2, mitotic arrest deficient 2; MEFs, murine embryonic fibroblasts; MOMP, mitochondrial outer membrane permeabilization; PLK1-I, Polo-Like kinase 1 inhibitor; SAC, spindle-assembly checkpoint.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank staff at the SA Pathology animal resource facility for help in maintaining the mouse strains and members of our laboratory for discussions and useful comments. Funding for this work was provided by the National Health and Medical Research Council project grant (1043057) and a Senior Principal Research Fellowship (1103006) to Sharad Kumar. Loretta Dorstyn was a Cancer Council Research Fellow and Swati Dawar is supported by a UniSA Presidential Award.

AUTHOR CONTRIBUTIONS

Swati Dawar carried out most experiments and collected data; Yoon Lim carried out BiFC, immunoblotting experiments, clonogenic assays and characterized *Casp2*^{C320S} mice; Joseph Puccini generated *Atm*^{-/-}, *Atm*^{-/-}/*Casp2*^{-/-} lymphoma cells; Joseph Puccini, Melissa White and Paul Thomas helped generate *Casp2*^{C320S} mice; Lisa Bouchier-Hayes and Douglas R. Green contributed BiFC reagents and advice; Loretta Dorstyn and Sharad Kumar designed and supervised the study, analysed data and wrote the paper. All authors discussed the results and commented on the manuscript.

REFERENCES

- Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. *Nat Rev Genet* 2012; **13**: 189–203.

- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646–674.
- Geigl JB, Obenaus AC, Schwarzbraun T, Speicher MR. Defining 'chromosomal instability'. *Trends Genet* 2008; **24**: 64–69.
- Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. *Nat Rev Mol Cell Biol* 2009; **10**: 478–487.
- Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, Yakushijin K *et al*. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. *Oncogene* 2004; **23**: 4362–4370.
- Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. *Nat Rev Mol Cell Biol* 2011; **12**: 385–392.
- Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. *Oncogene* 2004; **23**: 2825–2837.
- Decordier I, Dillen L, Cundari E, Kirsch-Volders M. Elimination of micronucleated cells by apoptosis after treatment with inhibitors of microtubules. *Mutagenesis* 2002; **17**: 337–344.
- Giam M, Rancati G. Aneuploidy and chromosomal instability in cancer. *Cell Div* 2015; **10**: 3.
- Li M, Zhang P. Spindle assembly checkpoint, aneuploidy and tumorigenesis. *Cell Cycle* 2009; **8**: 3440.
- Baliga BC, Read SH, Kumar S. The biochemical mechanism of caspase-2 activation. *Cell Death Differ* 2004; **11**: 1234–1241.
- Kumar S. Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma no more? *Nat Rev Cancer* 2009; **9**: 897–903.
- Dorstyn L, Puccini J, Wilson CH, Shalini S, Nicola M, Moore S *et al*. Caspase-2 deficiency promotes aberrant DNA-damage response and genetic instability. *Cell Death Differ* 2012; **19**: 1288–1298.
- Ho LH, Taylor R, Dorstyn L, Cakouros D, Bouillet P, Kumar S. A tumor suppressor function for caspase-2. *Proc Natl Acad Sci USA* 2009; **106**: 5336–5341.
- Yoo BH, Wang Y, Erdogan M, Sasazuki T, Shirasawa S, Corcos L *et al*. Oncogenic ras-induced down-regulation of pro-apoptotic protease caspase-2 is required for malignant transformation of intestinal epithelial cells. *J Biol Chem* 2011; **286**: 38894–38903.
- Ho LH, Read SH, Dorstyn L, Lambrusco L, Kumar S. Caspase-2 is required for cell death induced by cytoskeletal disruption. *Oncogene* 2008; **27**: 3393–3404.
- Manzl C, Peintner L, Krumschnabel G, Bock F, Labi V, Drach M *et al*. PI3Dosome-independent tumor suppression by Caspase-2. *Cell Death Differ* 2012; **19**: 1722–1732.
- Parsons MJ, McCormick L, Janke L, Howard A, Bouchier-Hayes L, Green DR. Genetic deletion of caspase-2 accelerates MMTV/c-neu-driven mammary carcinogenesis in mice. *Cell Death Differ* 2013; **20**: 1174–1182.
- Puccini J, Dorstyn L, Kumar S. Caspase-2 as a tumour suppressor. *Cell Death Differ* 2013; **20**: 1133–1139.
- Terry MR, Arya R, Mukhopadhyay A, Berrett KC, Clair PM, Witt B *et al*. Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo. *Cell Death Differ* 2015; **22**: 719–730.
- Puccini J, Shalini S, Voss AK, Gate M, Wilson CH, Hiwase DK *et al*. Loss of caspase-2 augments lymphomagenesis and enhances genomic instability in *Atm*-deficient mice. *Proc Natl Acad Sci USA* 2013; **110**: 19920–19925.
- Shalini S, Nikolic A, Wilson CH, Puccini J, Sladojevic N, Finnie J *et al*. Caspase-2 deficiency accelerates chemically induced liver cancer in mice. *Cell Death Differ* 2016; **23**: 1727–1736.
- Hamanaka R, Smith MR, O'Connor PM, Maloid S, Mihalic K, Spivak JL *et al*. Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. *J Biol Chem* 1995; **270**: 21086–21091.
- Wang Q, Xie S, Chen J, Fukasawa K, Naik U, Traganos F *et al*. Cell cycle arrest and apoptosis induced by human Polo-like kinase 3 is mediated through perturbation of microtubule integrity. *Mol Cell Biol* 2002; **22**: 3450–3459.
- Lu B, Mahmud H, Maass AH, Yu B, van Gilst WH, de Boer RA *et al*. The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro. *PLoS One* 2010; **5**: e12963.
- Wasch R, Hasskarl J, Schnerch D, Lubbert M. BI-2536 – targeting the mitotic kinase Polo-like kinase 1 (Plk1). *Recent Results Cancer Res* 2010; **184**: 215–218.
- Miki H, Okada Y, Hirokawa N. Analysis of the kinesin superfamily: insights into structure and function. *Trends Cell Biol* 2005; **15**: 467–476.
- Kanda T, Sullivan KF, Wahl GM. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. *Curr Biol* 1998; **8**: 377–385.
- Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. *Curr Biol* 2006; **16**: 1194–1200.
- Bouchier-Hayes L, Oberst A, McStay GP, Connell S, Tait SW, Dillon CP *et al*. Characterization of cytoplasmic caspase-2 activation by induced proximity. *Mol Cell* 2009; **35**: 830–840.

- 31 Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. *J Biol Chem* 2002; **277**: 13430–13437.
- 32 Robertson JD, Enoksson M, Suomela M, Zhivotovsky B, Orrenius S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. *J Biol Chem* 2002; **277**: 29803–29809.
- 33 Shalini S, Dorstyn L, Dawar S, Kumar S. Old, new and emerging functions of caspases. *Cell Death Differ* 2015; **22**: 526–539.
- 34 Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. *Science* 2002; **297**: 1352–1354.
- 35 Ren K, Lu J, Porollo A, Du C. Tumor-suppressing function of caspase-2 requires catalytic site Cys-320 and site Ser-139 in mice. *J Biol Chem* 2012; **287**: 14792–14802.
- 36 Andersen JL, Johnson CE, Freel CD, Parrish AB, Day JL, Buchakjian MR et al. Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2. *EMBO J* 2009; **28**: 3216–3227.
- 37 Mendelsohn AR, Hamer JD, Wang ZB, Brent R. Cyclin D3 activates Caspase 2, connecting cell proliferation with cell death. *Proc Natl Acad Sci USA* 2002; **99**: 6871–6876.
- 38 Taghiyev AF, Rokhlin OW, Glover RB. Caspase-2-based regulation of the androgen receptor and cell cycle in the prostate cancer cell line LNCaP. *Genes Cancer* 2011; **2**: 745–752.
- 39 Choi M, Kim W, Cheon MG, Lee CW, Kim JE. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells. *Cancer Lett* 2015; **357**: 591–601.
- 40 Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. *Cell Death Differ* 2009; **16**: 3–11.
- 41 Cimini D, Howell B, Maddox P, Khodjakov A, Degrossi F, Salmon ED. Merotelic kinetochore orientation is a major mechanism of aneuploidy in mitotic mammalian tissue cells. *J Cell Biol* 2001; **153**: 517–527.
- 42 Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. *Nature* 2009; **460**: 278–282.
- 43 Dobles M, Liberal V, Scott ML, Benezra R, Sorger PK. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. *Cell* 2000; **101**: 635–645.
- 44 Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. *Nature* 2001; **409**: 355–359.
- 45 Shalini S, Dorstyn L, Wilson C, Puccini J, Ho L, Kumar S. Impaired antioxidant defence and accumulation of oxidative stress in caspase-2-deficient mice. *Cell Death Differ* 2012; **19**: 1370–1380.
- 46 Zhang Y, Padalecki SS, Chaudhuri AR, De Waal E, Goins BA, Grubbs B et al. Caspase-2 deficiency enhances aging-related traits in mice. *Mech Ageing Dev* 2007; **128**: 213–221.
- 47 Palmisiano ND, Kasner MT. Polo-like kinase and its inhibitors: ready for the match to start? *Am J Hematol* 2015; **90**: 1071–1076.
- 48 Decordier I, Cundari E, Kirsch-Volders M. Survival of aneuploid, micronucleated and/or polyploid cells: crosstalk between ploidy control and apoptosis. *Mutat Res* 2008; **651**: 30–39.
- 49 Peterson SE, Yang AH, Bushman DM, Westra JW, Yung YC, Barral S et al. Aneuploid cells are differentially susceptible to caspase-mediated death during embryonic cerebral cortical development. *J Neurosci* 2012; **32**: 16213–16222.
- 50 Kaufmann T, Tai L, Ekert PG, Huang DC, Norris F, Lindemann RK et al. The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. *Cell* 2007; **129**: 423–433.
- 51 O'Reilly LA, Ekert P, Harvey N, Marsden V, Cullen L, Vaux DL et al. Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. *Cell Death Differ* 2002; **9**: 832–841.
- 52 Dorstyn L, Kumar S. Caspase-2 protocols. *Methods Mol Biol* 2014; **1133**: 71–87.
- 53 Parsons MJ, Bouchier-Hayes L. Measuring initiator caspase activation by bimolecular fluorescence complementation. *Cold Spring Harb Protoc* 2015; **2015**: pdb prot082552.
- 54 Belkhir A, Zhu S, Chen Z, Soutto M, El-Rifai W. Resistance to TRAIL is mediated by DARPP-32 in gastric cancer. *Clin Cancer Res* 2012; **18**: 3889–3900.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>

© The Author(s) 2017

Supplementary Information accompanies this paper on the Oncogene website (<http://www.nature.com/onc>)